Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (NYSE: DHR) will webcast its Fourth Quarter 2025 earnings conference call on Wednesday, January 28, 2026 at 8:00 a.m. ET, with an expected duration of about one hour.
The company will discuss financial performance and future expectations. The live webcast and accompanying slide presentation will be available in the Investors > Events & Presentations section at www.danaher.com. Webcast slides, the earnings press release, and related materials will be posted beginning at 6:00 a.m. ET on the day of the call.
Dial-in access: 800-245-3047 (U.S.) or +1 203-518-9765 (outside U.S.); Conference ID: DHRQ425. A replay of the webcast and call will be available after the presentation; the call replay remains available until February 11, 2026.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.32 per share. The dividend is payable on January 30, 2026 to holders of record on December 26, 2025.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 11:00 a.m. GMT.
The event will be simultaneously webcast and accessible via www.danaher.com, allowing investors and analysts to view the presentation live.
Danaher (NYSE: DHR) reported third quarter 2025 results for the period ended September 26, 2025. Revenue rose 4.5% YoY to $6.1B and non-GAAP core revenue increased 3.0% YoY. Net earnings were $908M, or $1.27 per diluted share; adjusted diluted EPS was $1.89. Operating cash flow was $1.7B and non-GAAP free cash flow was $1.4B. The company maintained full‑year 2025 adjusted diluted EPS guidance of $7.70–$7.80 and expects non‑GAAP core revenue to grow in the low‑single digits for 2025. Management highlighted bioprocessing momentum and stronger respiratory revenue at Cepheid. The company disclosed estimated 2025 acquisition amortization of $1.7B and an estimated +1.0% FX sales impact for the full year.
Danaher (NYSE:DHR) has scheduled its Q3 2025 earnings conference call for October 21, 2025 at 8:00 a.m. ET. The one-hour call will include discussions on financial performance and future outlook. The presentation will be accessible via webcast on Danaher's website under the "Investors" section.
Participants can join by dialing 800-245-3047 (U.S.) or +1 203-518-9765 (international). The earnings materials, including press release, slides, Form 10-Q, and non-GAAP reconciliations, will be available on the company's website at 6:00 a.m. ET on the call date. A replay will be available until November 4, 2025.
Beckman Coulter Diagnostics, a Danaher (NYSE:DHR) company, has launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. The test is available on the DxI 9000 Immunoassay Analyzer and Access 2 Analyzer platforms.
BD-Tau represents a significant advancement in neurodegenerative research, offering enhanced specificity compared to traditional tau markers. The test directly detects brain-derived tau in blood, providing a more precise indicator of neurodegeneration. Additionally, the company announced the development of an Aβ-42 RUO immunoassay test, marking progress toward their FDA Breakthrough Device Designation for a p-Tau 217/Aβ-42 ratio test.
Danaher Corporation (NYSE: DHR) has announced its Board of Directors approved a regular quarterly cash dividend of $0.32 per share of common stock. The dividend will be paid on October 31, 2025 to shareholders of record as of September 26, 2025.
Danaher (NYSE: DHR) has appointed Jonathan Leiken as Senior Vice President and General Counsel, effective August 25, 2025. Leiken, who brings nearly three decades of legal and leadership experience, will report to CEO Rainer Blair and join the Danaher Leadership Team.
Leiken succeeds Brian Ellis, who will retire after nearly 10 years as General Counsel. Ellis will remain with Danaher through February 2026 to support the transition. Prior to joining Danaher, Leiken served as Executive VP and Chief Legal Officer at Dollar Tree and Diebold Nixdorf, and has experience as a federal prosecutor and law firm partner.
Danaher (NYSE: DHR) announced that Matthew Gugino will succeed Matthew McGrew as Chief Financial Officer, effective February 28th, 2026. Gugino, currently Group CFO of Life Sciences Innovations Group and VP of Financial Planning & Analysis, brings extensive experience in Investor Relations, FP&A, and M&A.
McGrew, who has served as CFO since 2019, will transition to an Executive VP role as he approaches retirement after 20+ years with the company. During his CFO tenure, Danaher nearly doubled both revenue and market capitalization while improving growth and margin profiles. McGrew played key roles in the Cytiva acquisition and the launches of Envista and Veralto.
Danaher (NYSE: DHR) reported strong second quarter 2025 results, with revenues increasing 3.5% year-over-year to $5.9 billion and non-GAAP core revenue growth of 1.5%. The company posted net earnings of $555 million, or $0.77 per diluted share, while non-GAAP adjusted diluted earnings reached $1.80 per share.
Operating cash flow stood at $1.3 billion, with non-GAAP free cash flow of $1.1 billion. For full year 2025, Danaher maintains its core revenue growth forecast of approximately 3% and has raised its adjusted EPS guidance to $7.70-$7.80 from the previous $7.60-$7.75. The company expects low-single-digit core revenue growth for Q3 2025.